The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://mohamadxyjt205611.fitnell.com/79882065/glp-3-retatrutide-a-comparative-analysis